nach oben

Current Hypertension Reports

Erschienen in:

01.05.2015 | Hypertension and the Brain (S Stocker, Section Editor)

Control of Energy Balance by the Brain Renin-Angiotensin System

verfasst von: Kristin E. Claflin, Justin L. Grobe

Erschienen in: Current Hypertension Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The renin-angiotensin system (RAS) exists as a circulating hormone system but it is also used by various tissues of the body, including the brain, as a paracrine signaling mechanism. The local brain version of the RAS is mechanistically involved in fluid balance and blood pressure control, and there is growing appreciation for a role of the brain RAS in the control of energy balance. Here, we review major evidence for the control of energy balance by the brain RAS; outline the current understanding of the RAS components, targets, and mechanisms involved; and highlight some major questions that currently face the field.

Jung RT. Obesity as a disease. Br Med Bull. 1997;53(2):307–21.PubMedCrossRef

Huffman MD, Capewell S, Ning H, Shay CM, Ford ES, Lloyd-Jones DM. Cardiovascular health behavior and health factor changes (1988–2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation. 2012;125(21):2595–602. doi:https://doi.org/10.1161/CIRCULATIONAHA.111.070722.PubMedPubMedCentralCrossRef

Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. Faseb J. 2001;15(14):2727–9. doi:https://doi.org/10.1096/fj.01-0457fje.PubMedCrossRef

Faloia E, Gatti C, Camilloni MA, Mariniello B, Sardu C, Garrapa GG, et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Investig. 2002;25(4):309–14.CrossRef

Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev: Off J Int Assoc Study Obes. 2003;4(1):43–55.CrossRef

Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased Ventri Ectopy Cardiopathy Obes Archives Int Med. 1987;147(10):1725–8.CrossRef

Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995;95(3):948–53. doi:https://doi.org/10.1172/JCI117803.PubMedPubMedCentralCrossRef

Cooper R, McFarlane-Anderson N, Bennett FI, Wilks R, Puras A, Tewksbury D, et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J Hum Hypertens. 1997;11(2):107–11.PubMedCrossRef

Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62. doi:https://doi.org/10.1161/01.HYP.0000154361.47683.d3.PubMedCrossRef

10.

Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, et al. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab. 2007;6(6):506–12. doi:https://doi.org/10.1016/j.cmet.2007.10.011.PubMedPubMedCentralCrossRef

11.

Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology. 2001;142(12):5220–5. doi:https://doi.org/10.1210/endo.142.12.8556.PubMedCrossRef

12.

Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A. 2008;105(18):6531–6. doi:https://doi.org/10.1073/pnas.0802690105.PubMedPubMedCentralCrossRef

13.

Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology. 2005;146(8):3481–9. doi:https://doi.org/10.1210/en.2005-0003.PubMedCrossRef

14.

Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav. 2009;98(1–2):192–7. doi:https://doi.org/10.1016/j.physbeh.2009.05.009.PubMedCrossRef

15.

Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol. 2006;552(1–3):112–22. doi:https://doi.org/10.1016/j.ejphar.2006.08.062.PubMedPubMedCentralCrossRef

16.

Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS. Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol. 2009;158(3):771–8. doi:https://doi.org/10.1111/j.1476-5381.2009.00355.x.PubMedPubMedCentralCrossRef

17.

Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes. 2008;32(10):1576–84. doi:https://doi.org/10.1038/ijo.2008.126.CrossRef

18.

Santos EL, de Picoli SK, Guimaraes PB, Reis FC, Silva SM, Costa-Neto CM, et al. Effect of angiotensin converting enzyme inhibitor enalapril on body weight and composition in young rats. Int Immunopharmacol. 2008;8(2):247–53. doi:https://doi.org/10.1016/j.intimp.2007.07.021.PubMedCrossRef

19.

Gratze P, Boschmann M, Dechend R, Qadri F, Malchow J, Graeske S, et al. Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity? Hypertension. 2009;53(3):516–23. doi:https://doi.org/10.1161/HYPERTENSIONAHA.108.124966.PubMedCrossRef

20.

Laragh JH. Biochemical profiling and the natural history of hypertensive diseases: low-renin essential hypertension, a benign condition. Circulation. 1971;44(6):971–4.PubMedCrossRef

21.

Jamerson KA. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis: Off J Ntnl Kidney Foundation. 2000;36(3 Suppl 1):S24–30.CrossRef

22.

Karlberg BE, Asplund J, Wettre S, Ohman KP, Nilsson OR. Long-term experience of captopril in the treatment of primary (essential) hypertension. Br J Clin Pharmacol. 1982;14 Suppl 2:133S–7.PubMedPubMedCentralCrossRef

23.

Mizuno K, Haruyama K, Gotoh M, Matsui J, Fukuchi S. Evidence for the role of kinins in the acute antihypertensive effect of captopril in low-renin hypertension. Jpn Heart J. 1984;25(3):379–86.PubMedCrossRef

24.

Gomez HJ, Smith 3rd SG, Moncloa F. Efficacy and safety of lisinopril in older patients with essential hypertension. Am J Med. 1988;85(3B):35–7.PubMedCrossRef

25.

Gohlke P, Ganten D, Lang RE, Unger T. The renin-angiotensin system: systemic and local function. Z Kardiol. 1988;77 Suppl 3:1–12.PubMed

26.

Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integrat Comparat Physiol. 2012;302(5):R518–30. doi:https://doi.org/10.1152/ajpregu.00525.2011.CrossRef

27.

Buckley RBJ. Evidence for a central mechanism in angiotensin-induced hypertension. Proc Soc Exp Biol Med. 1961;106:834–7.CrossRef

28.

Booth D. Mechanisms of action of norepinephrine in eliciting an eating response on injection into the rat hypothalamus. J Pharmacol Exp Ther. 1968;160:336–48.PubMed

29.

Epstein AN, Fitzsimons JT, Rolls BJ. Drinking induced by injection of angiotensin into the rain of the rat. J Physiol. 1970;210(2):457–74.PubMedPubMedCentralCrossRef

30.

Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol. 1998;274(5 Pt 1):E867–76.PubMed

31.

Porter JP, Anderson JM, Robison RJ, Phillips AC. Effect of central angiotensin II on body weight gain in young rats. Brain Res. 2003;959(1):20–8.PubMedCrossRef

32.

Porter JP, Potratz KR. Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats. Am J Physiol Regulat, Integrat Comparat Physiol. 2004;287(2):R422–8. doi:https://doi.org/10.1152/ajpregu.00537.2003.CrossRef

33.

Ferguson AV, Washburn DL, Latchford KJ. Hormonal and neurotransmitter roles for angiotensin in the regulation of central autonomic function. Exp Biol Med (Maywood, NJ). 2001;226(2):85–96.CrossRef

34.

Ferguson AV. Angiotensinergic regulation of autonomic and neuroendocrine outputs: critical roles for the subfornical organ and paraventricular nucleus. Neuroendocrinology. 2009;89(4):370–6. doi:https://doi.org/10.1159/000211202.PubMedCrossRef

35.

Coble JP, Grobe JL, Johnson AK, Sigmund CD. Mechanisms of brain renin angiotensin system-induced drinking and blood pressure: importance of the subfornical organ. Am J Physiol Regulaty, Integrat Comparat Physiol. 2014. doi:https://doi.org/10.1152/ajpregu.00486.2014.PubMedCrossRef

36.

Fischer-Ferraro C, Nahmod VE, Goldstein DJ, Finkielman S. Angiotensin and renin in rat and dog brain. J Exp Med. 1971;133(2):353–61.PubMedPubMedCentralCrossRef

37.

Ganten D, Boucher R, Genest J. Renin activity in brain tissue of puppies and adult dogs. Brain Res. 1971;33(2):557–9.PubMedCrossRef

38.

Ganten D, Marquez-Julio A, Granger P, Hayduk K, Karsunky KP, Boucher R, et al. Renin in dog brain. Am J Physiol. 1971;221(6):1733–7.PubMedCrossRef

39.

Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system—an endocrine and paracrine system. Endocrinology. 2003;144(6):2179–83. doi:https://doi.org/10.1210/en.2003-0150.PubMedCrossRef

40.

Yang HY, Neff NH. Distribution and properties of angiotensin converting enzyme of rat brain. J Neurochem. 1972;19(10):2443–50.PubMedCrossRef

41.

Poth MM, Heath RG, Ward M. Angiotensin-converting enzyme in human brain. J Neurochem. 1975;25(1):83–5.PubMedCrossRef

42.

Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta. 1971;250(1):261–5.PubMedCrossRef

43.

Fuxe K, Ganten D, Hokfelt T, Bolme P. Immunohistochemical evidence for the existence of angiotensin II-containing nerve terminals in the brain and spinal cord in the rat. Neurosci Lett. 1976;2(4):229–34.PubMedCrossRef

44.

Healy DP, Printz MP. Distribution of immunoreactive angiotensin II, angiotensin I, angiotensinogen and nephrectomized rats. Hypertension. 1984;6(2 Pt 2):I130–6.PubMed

45.

Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000;106(1):103–6. doi:https://doi.org/10.1172/JCI10022.PubMedPubMedCentralCrossRef

46.

Mimee A, Smith PM, Ferguson AV. Circumventricular organs: targets for integration of circulating fluid and energy balance signals? Physiol Behav. 2013;121:96–102. doi:https://doi.org/10.1016/j.physbeh.2013.02.012.PubMedCrossRef

47.

Mangiapane ML, Simpson JB. Subfornical organ: forebrain site of pressor and dipsogenic action of angiotensin II. Am J Physiol. 1980;239(5):R382–9.PubMed

48.

Simpson JB, Routtenberg A. Subfornical organ: site of drinking elicitation by angiotensin II. Science. 1973;181(4105):1172–5.PubMedCrossRef

49.

Coble JP, Cassell MD, Davis DR, Grobe JL, Sigmund CD. Activation of the renin-angiotensin system, specifically in the subfornical organ is sufficient to induce fluid intake. Am J Physiol Regulat, Integrat comparat Physiol. 2014;307(4):R376–86. doi:https://doi.org/10.1152/ajpregu.00216.2014.CrossRef

50.

Oka Y, Ye M, Zuker CS. Thirst driving and suppressing signals encoded by distinct neural populations in the brain. Nature. 2015. doi:https://doi.org/10.1038/nature14108.PubMedPubMedCentralCrossRef

51.

Hilzendeger AM, Cassell MD, Davis DR, Stauss HM, Mark AL, Grobe JL, et al. Angiotensin type 1a receptors in the subfornical organ are required for deoxycorticosterone acetate-salt hypertension. Hypertension. 2013;61(3):716–22. doi:https://doi.org/10.1161/HYPERTENSIONAHA.111.00356.PubMedCrossRef

52.

Braga VA, Medeiros IA, Ribeiro TP, Franca-Silva MS, Botelho-Ono MS, Guimaraes DD. Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. Brazilian J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica. 2011;44(9):871–6.

53.

Muratani H, Ferrario CM, Averill DB. Ventrolateral medulla in spontaneously hypertensive rats: role of angiotensin II. Am J Physiol. 1993;264(2 Pt 2):R388–95.PubMed

54.

Zhu DN, Moriguchi A, Mikami H, Higaki J, Ogihara T. Central amino acids mediate cardiovascular response to angiotensin II in the rat. Brain Res Bull. 1998;45(2):189–97.PubMedCrossRef

55.

Konno S, Hirooka Y, Kishi T, Sunagawa K. Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. J Hypertens. 2012;30(10):1992–9. doi:https://doi.org/10.1097/HJH.0b013e328357fa98.PubMedCrossRef

56.

Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, et al. Local production of angiotensin II in the subfornical organ causes elevated drinking. J Clin Invest. 2007;117(4):1088–95. doi:https://doi.org/10.1172/jci31242.PubMedPubMedCentralCrossRef

57.

Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, Xu D, et al. The brain renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab. 2010;12(5):431–42. doi:https://doi.org/10.1016/j.cmet.2010.09.011.PubMedPubMedCentralCrossRef

58.

Littlejohn NK, Siel Jr RB, Ketsawatsomkron P, Pelham CJ, Pearson NA, Hilzendeger AM, et al. Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. Am J Physiol Regulat, Integrat comparat Physiol. 2013;304(10):R818–28. doi:https://doi.org/10.1152/ajpregu.00082.2013.CrossRef

59.

Boschmann M, Engeli S, Adams F, Franke G, Luft FC, Sharma AM, et al. Influences of AT1 receptor blockade on tissue metabolism in obese men. Am J Physiol Regulat, Integrat comparat Physiol. 2006;290(1):R219–23. doi:https://doi.org/10.1152/ajpregu.00341.2005.CrossRef

60.

Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25(4):841–8. doi:https://doi.org/10.1097/HJH.0b013e3280287a83.PubMedCrossRef

61.

Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens. 2010;12(9):746–52. doi:https://doi.org/10.1111/j.1751-7176.2010.00335.x.CrossRef

62.•

Marinik EL, Frisard MI, Hulver MW, Davy BM, Rivero JM, Savla JS, et al. Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure. Ther Adv Cardiovasc Dis. 2013;7(1):11–20. doi:https://doi.org/10.1177/1753944712471740. This report revealed that administration of angiotensin receptor blockers does not reduce body weight or BMI in obese human patients.PubMedCrossRef

63.

Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther. 2007;24(1):146–53.PubMedCrossRef

64.

Grassi G, Seravalle G, Dell’Oro R, Trevano FQ, Bombelli M, Scopelliti F, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21(9):1761–9. doi:https://doi.org/10.1097/01.hjh.0000084718.53355.69.PubMedCrossRef

65.

Cassis L, Helton M, English V, Burke G. Angiotensin II regulates oxygen consumption. Am J Physiol Regulat, Integrat comparat Physiol. 2002;282(2):R445–53. doi:https://doi.org/10.1152/ajpregu.00261.2001.CrossRef

66.

Yoshida T, Semprun-Prieto L, Wainford RD, Sukhanov S, Kapusta DR, Delafontaine P. Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology. 2012;153(3):1411–20. doi:https://doi.org/10.1210/en.2011-1764.PubMedPubMedCentralCrossRef

67.

de Kloet AD, Krause EG, Scott KA, Foster MT, Herman JP, Sakai RR, et al. Central angiotensin II has catabolic action at white and brown adipose tissue. Am J Physiol Endocrinol Metab. 2011;301(6):E1081–91. doi:https://doi.org/10.1152/ajpendo.00307.2011.PubMedPubMedCentralCrossRef

68.

Ohinata K, Fujiwara Y, Fukumoto S, Iwai M, Horiuchi M, Yoshikawa M. Angiotensin II and III suppress food intake via angiotensin AT(2) receptor and prostaglandin EP(4) receptor in mice. FEBS Lett. 2008;582(5):773–7. doi:https://doi.org/10.1016/j.febslet.2008.01.054.PubMedCrossRef

69.

Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 2005;54(4):991–9.PubMedCrossRef

70.

de Kloet AD, Wang L, Ludin JA, Smith JA, Pioquinto DJ, Hiller H, et al. Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. Brain Struct Funct. 2014. doi:https://doi.org/10.1007/s00429-014-0943-1.PubMedCrossRef

71.

Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T. Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Physiol. 1986;251(2 Pt 2):H261–8.PubMed

72.

Kubo T, Yamaguchi H, Tsujimura M, Hagiwara Y, Fukumori R. Blockade of angiotensin receptors in the anterior hypothalamic preoptic area lowers blood pressure in DOCA-salt hypertensive rats. Hypertens Res: Off J Jpn Soc Hypertens. 2000;23(2):109–18.CrossRef

73.

Park CG, Leenen FH. Effects of centrally administered losartan on deoxycorticosterone-salt hypertension rats. J Korean Med Sci. 2001;16(5):553–7.PubMedPubMedCentralCrossRef

74.

Grobe JL, Buehrer BA, Hilzendeger AM, Liu X, Davis DR, Xu D, et al. Angiotensinergic signaling in the brain mediates metabolic effects of deoxycorticosterone (DOCA)-salt in C57 mice. Hypertension. 2011;57(3):600–7. doi:https://doi.org/10.1161/HYPERTENSIONAHA.110.165829.PubMedCrossRef

75.••

de Kloet AD, Pati D, Wang L, Hiller H, Sumners C, Frazier CJ, et al. Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity. J Neurosci: Off J Soc Neurosci. 2013;33(11):4825–33. doi:https://doi.org/10.1523/JNEUROSCI.3806-12.2013. This study used mouse models to selectively delete the AT1A receptor from any cell expressing the Sim1 promoter and revealed that deletion of the brain RAS in these specific brain regions increased sensitivity to diet-induced obesity.CrossRef

76.

Thatcher S, Yiannikouris F, Gupte M, Cassis L. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302(2):111–7.PubMedPubMedCentralCrossRef

77.

Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regulat, Integrat comparat Physiol. 2004;287(4):R943–9. doi:https://doi.org/10.1152/ajpregu.00265.2004.CrossRef

78.

Farooqi IS, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutrit. 2009;89(3):980S–4. doi:https://doi.org/10.3945/ajcn.2008.26788C.PubMedCrossRef

79.

Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, et al. Leptin mediates the increase in blood pressure associated with obesity. Cell. 2014;159(6):1404–16. doi:https://doi.org/10.1016/j.cell.2014.10.058.PubMedPubMedCentralCrossRef

80.

Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000;105(9):1243–52. doi:https://doi.org/10.1172/JCI8341.PubMedPubMedCentralCrossRef

81.

da Silva AA, do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens. 2013;22(2):135–40. doi:https://doi.org/10.1097/MNH.0b013e32835d0c05.PubMedPubMedCentralCrossRef

82.

Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100(2):270–8. doi:https://doi.org/10.1172/JCI119532.PubMedPubMedCentralCrossRef

83.

Swoap SJ. Altered leptin signaling is sufficient, but not required, for hypotension associated with caloric restriction. Am J Physiol Heart Circulat Physiol. 2001;281(6):H2473–9.CrossRef

84.

Hilzendeger AM, Morais RL, Todiras M, Plehm R, da Costa GA, Qadri F, et al. Leptin regulates ACE activity in mice. J Mol Med. 2010;88(9):899–907. doi:https://doi.org/10.1007/s00109-010-0649-7.PubMedCrossRef

85.

McKinley MJ, Allen AM, Clevers J, Paxinos G, Mendelsohn FA. Angiotensin receptor binding in human hypothalamus: autoradiographic localization. Brain Res. 1987;420(2):375–9.PubMedCrossRef

86.

Arakawa H, Chitravanshi VC, Sapru HN. The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1–12) and angiotensin II. Am J Physiol Heart Circulat Physiol. 2011;300(3):H951–60. doi:https://doi.org/10.1152/ajpheart.01144.2010.CrossRef

87.

Hilzendeger AM, Morgan DA, Brooks L, Dellsperger D, Liu X, Grobe JL, et al. A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. Am J Physiol Heart Circulat Physiol. 2012;303(2):H197–206. doi:https://doi.org/10.1152/ajpheart.00974.2011.CrossRef

88.••

Young CN, Morgan DA, Butler SD, Rahmouni K, Gurley SB, Coffman TM, et al. Angiotensin type 1a receptors in the forebrain subfornical organ facilitate leptin-induced weight loss through brown adipose tissue thermogenesis. Mol Metab. 2015. doi:https://doi.org/10.1016/j.molmet.2015.01.007. These studies demonstrate that angiotensin signaling mediated by the AT1A receptor is required for leptin-mediated sympathetic activation of brown adipose tissue supporting a role for the interaction between leptin and angiotensin signaling in metabolic rate control.PubMedPubMedCentralCrossRef

89.

Young CN, Morgan DA, Butler SD, Mark AL, Davisson RL. The brain subfornical organ mediates leptin-induced increases in renal sympathetic activity but not its metabolic effects. Hypertension. 2013;61(3):737–44. doi:https://doi.org/10.1161/HYPERTENSIONAHA.111.00405.PubMedCrossRef

Titel: Control of Energy Balance by the Brain Renin-Angiotensin System
verfasst von: Kristin E. Claflin
Justin L. Grobe
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 5/2015
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-015-0549-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Control of Energy Balance by the Brain Renin-Angiotensin System

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Hypertension in Pregnancy: Natural History and Treatment Options

Assessment of Right Ventricular Function in Pulmonary Hypertension

Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome

Hypothalamic Signaling Mechanisms in Hypertension

LCZ696: The Next Step in Improving RAS Inhibition?

Capillary Rarefaction as an Index for the Microvascular Assessment of Hypertensive Patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin